Intervention/Treatment: The trial tests Itepekimab, administered subcutaneously in high and low doses, alongside Mometasone furoate nasal spray. The purpose is to improve symptoms in patients with ...

Sanofi’s commitment to sustainability has been recognized globally, with TIME ranking it as the world’s 10th most sustainable company across all industries and #1 in pharma and biotech. This accolade ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 22% to $4.34 billion EYLEA HD® U.S. net sales increased ...

In 2025, sales are anticipated to grow by a high single-digit percentage at CER (previously mid-to-high single-digit). Sanofi confirms the expectation of a strong business EPS rebound with growth at a ...

On May 30, 2025, Sanofi issued a press release announced mixed data from a Phase 3 program for itepekimab, an antibody therapy targeting the lung disorder chronic obstructive pulmonary disease.

The European Commission has approved Sanofi’s Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the induction treatment of adult patients with newly diagnosed multiple ...

Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction ...

Goodwin Procter, Linklaters and Cooley are advising on French drugmaker Sanofi's agreement to buy British vaccine biotech Vicebio for up to $1.6 billion, contingent on hitting development and ...

French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total of $1.15 billion, expanding its respiratory vaccine portfolio.